# BP-C1 Monotherapy in Patients With Metastatic Breast Cancer Cancer: Estimation of Optimal Duration of Treatment

> **NCT03789019** · PHASE2 · COMPLETED · sponsor: **Meabco A/S** · enrollment: 29 (actual)

## Conditions studied

- Metastatic Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **DRUG:** BP-C1

## Key facts

- **NCT ID:** NCT03789019
- **Lead sponsor:** Meabco A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-22
- **Primary completion:** 2016-07-29
- **Final completion:** 2016-07-29
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2019-10-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03789019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03789019, "BP-C1 Monotherapy in Patients With Metastatic Breast Cancer Cancer: Estimation of Optimal Duration of Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03789019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*